메뉴 건너뛰기




Volumn 50, Issue 2, 2006, Pages 632-638

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CILASTATIN PLUS IMIPENEM;

EID: 31944441962     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.632-638.2006     Document Type: Article
Times cited : (189)

References (19)
  • 2
    • 0345201630 scopus 로고    scopus 로고
    • In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
    • Chavez, M., S. Bernal, A. Valverde, M. J. Gutierrez, G. Quindos, and E. M. Mazuelos. 1999. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J. Antimicrob. Chemother. 44:697-700.
    • (1999) J. Antimicrob. Chemother. , vol.44 , pp. 697-700
    • Chavez, M.1    Bernal, S.2    Valverde, A.3    Gutierrez, M.J.4    Quindos, G.5    Mazuelos, E.M.6
  • 3
    • 0033825590 scopus 로고    scopus 로고
    • Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
    • Cuenca-Estrella, M., E. Mellado, T. M. Diaz-Guerra, A. Monzon, and J. L. Rodriguez-Tudela. 2000. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J. Antimicrob. Chemother. 46:475-477.
    • (2000) J. Antimicrob. Chemother. , vol.46 , pp. 475-477
    • Cuenca-Estrella, M.1    Mellado, E.2    Diaz-Guerra, T.M.3    Monzon, A.4    Rodriguez-Tudela, J.L.5
  • 4
    • 16844366147 scopus 로고    scopus 로고
    • Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine
    • Dowell, J. A., M. Stogniew, D. Krause, T. Henkel, and I. E. Weston. 2005. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin, Pharmacol. 45:227-233.
    • (2005) J. Clin, Pharmacol. , vol.45 , pp. 227-233
    • Dowell, J.A.1    Stogniew, M.2    Krause, D.3    Henkel, T.4    Weston, I.E.5
  • 6
    • 0031689491 scopus 로고    scopus 로고
    • Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
    • Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
    • (1998) J. Clin. Microbiol. , vol.36 , pp. 2950-2956
    • Espinel-Ingroff, A.1
  • 7
    • 0034812542 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
    • Groll, A. H., D. Mickiene, R. Petraitiene, V. Petraitis, C. A. Lyman, J. S. Bacher, S. C. Piscitelli, and T. J. Walsh. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45:2845-2855.
    • (2001) Antimicrob. Agents Chemother. , vol.45 , pp. 2845-2855
    • Groll, A.H.1    Mickiene, D.2    Petraitiene, R.3    Petraitis, V.4    Lyman, C.A.5    Bacher, J.S.6    Piscitelli, S.C.7    Walsh, T.J.8
  • 9
    • 0035239765 scopus 로고    scopus 로고
    • In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species
    • Moore, C. B., K. L. Oakley, and D. W. Denning. 2001. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin. Microbiol. Infect. 7:11-16.
    • (2001) Clin. Microbiol. Infect. , vol.7 , pp. 11-16
    • Moore, C.B.1    Oakley, K.L.2    Denning, D.W.3
  • 10
    • 33646783722 scopus 로고    scopus 로고
    • [Online.] National Institutes of Health, Bethesda, Md.
    • National Institutes of Health. 1999. Common toxicity criteria for adverse events, v2.0. [Online.] National Institutes of Health, Bethesda, Md. http://ctep.cancer.gov/reporting/.
    • (1999) Common Toxicity Criteria for Adverse Events, V2.0
  • 15
    • 0031943562 scopus 로고    scopus 로고
    • In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
    • Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
    • (1998) Diagn. Microbiol. Infect. Dis. , vol.30 , pp. 251-255
    • Pfaller, M.A.1    Marco, F.2    Messer, S.A.3    Jones, R.N.4
  • 19
    • 0030896919 scopus 로고    scopus 로고
    • In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis. and Aspergillus species
    • Zhanel, G. G., J. A. Karlowsky, G. A. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis. and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , pp. 863-865
    • Zhanel, G.G.1    Karlowsky, J.A.2    Harding, G.A.3    Balko, T.V.4    Zelenitsky, S.A.5    Friesen, M.6    Kabani, A.7    Turik, M.8    Hoban, D.J.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.